1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential
Drug Metabolism and Disposition · 2024
DOI: 10.1124/dmd.124.001680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2024. Verfasst von Yongjun Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol-Myers Squibb, Princeton, New Jersey (Y.X., L.W., R.H., B.M., A.G., J.X.S.); Regeneron P…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Drug Interactions, Biomarkers, Deoxycholic Acid. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol-Myers Squibb, Princeton, New Jersey (Y.X., L.W., R.H., B.M., A.G., J.X.S.); Regeneron Pharmaceuticals Inc., Tarrytown, New York (M.C.); and Pharmaceutical Ca…
Zitieren
APA
Xue, Y., Wang, L., Huo, R., Chen, M., Melo, B., Dingley, K., Gaudy, A., & Shen, J. X. (2024). 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.124.001680
Vancouver
Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K, et al. 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential. Drug Metabolism and Disposition. 2024. doi:10.1124/dmd.124.001680
BibTeX
@article{Xue2024,
author = {Xue, Yongjun and Wang, Linna and Huo, Runlan and Chen, Mu and Melo, Brian and Dingley, Karen and Gaudy, Allison and Shen, Jim X},
title = {1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential},
journal = {Drug Metabolism and Disposition},
year = {2024},
doi = {10.1124/dmd.124.001680}
}
EUVIMED